Celcuity Inc (CELC) USD0.001

Sell:$10.85Buy:$13.48$0.12 (0.93%)

Prices delayed by at least 15 minutes
Sell:$10.85
Buy:$13.48
Change:$0.12 (0.93%)
Prices delayed by at least 15 minutes
Sell:$10.85
Buy:$13.48
Change:$0.12 (0.93%)
Prices delayed by at least 15 minutes

Company Information

About this company

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Key people

Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Lance G. Laing
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Vicky Hahne
Chief Financial Officer
Eldon C. Mayer
Chief Commercial Officer
Richard E. Buller
Independent Director
David F. Dalvey
Independent Director
Leo T. Furcht
Independent Director
Polly A. Murphy
Independent Director
Richard J. Nigon
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US15102K1007
  • Market cap
    $478.23m
  • Employees
    55
  • Shares in issue
    37.13m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.